Previous 10 | Next 10 |
home / stock / gsk / gsk articles
Biotech company Acuitas Therapeutics has filed a lawsuit in Virginia federal court against Germany-based CureVac SE (NASDAQ: CV...
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a positive opinion recommending approv...
Stocks experienced a modest surge amid the Federal Open Market Committee meeting Wednesday. The central bank is widely expected to leave interest r...
The see-sawing sentiment continues as index futures pull back ahead of the all-important rate decision from the Federal Reserve. Some negative earn...
GSK plc (NYSE: GSK) and Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) have reached an agreement with Janssen Pharmaceu...
GSK plc (NYSE: GSK) released headline results from a planned analysis of Part 1 of the RUBY phase 3 trial of Jemperli (dostarlimab) ...
GSK (NYSE: GSK) has reportedly taken an early lead in the race for respiratory syncytial virus (RSV) vaccine dominance, surpassing Pfizer...
The third-quarter earnings season has largely been mixed so far, reflecting the impact of the economic uncertainties on profit growth. That said, d...
Several entities have included the Secure and Fair Enforcement Regulation (SAFER) Banking Act on their lobbying disclosures for the third...
News, Short Squeeze, Breakout and More Instantly...
2024-07-22 02:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-17 08:00:00 ET GSK (NYSE: GSK) , a global healthcare powerhouse, has been on a transformative journey since CEO Emma Walmsley took the helm in 2017. Despite its shares badly underperforming the S&P 500 under her first few years as CEO (see graph below), Walmsley's am...
2024-07-11 23:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...